GEN Exclusives

More »

GEN News Highlights

More »
Dec 27, 2011

Pfizer, Karo Bio Ally for Autoimmune Diseases

  • Karo Bio entered into a research collaboration agreement with Pfizer in the field of autoimmune diseases. Karo Bio may receive up to $217 million in up-front and milestone payments in addition to royalty fees.

    The focus will be on small molecule RORgamma modulators. Pfizer will provide full funding for research costs. It has the exclusive right to market any products that may be developed as a result of the collaboration.

    The nuclear hormone receptor RORgamma is a new target for the treatment of autoimmune diseases like rheumatoid arthritis and psoriasis. RORgamma directly controls the production and secretion of the cytokine IL-17, a major contributor to inflammation. The receptor’s key role in driving disease pathology has been implicated through clinical studies using mAbs that neutralize IL-17 activity.

    “The central role of RORgt in Th17 cell differentiation coupled with the increasing clinical validation for the importance of IL-17 and other Th17-derived cytokines in autoimmune diseases makes RORgt a compelling target,” says Jose-Carlos Gutierrez-Ramos, svp, biotherapeutics, worldwide R&D, Pfizer. “Combining KaroBio’s deep expertise in nuclear hormone receptors with the world-class chemistry and cytokine immunology expertise of Pfizer has the potential to accelerate our drug discovery effort in this competitive area.”

    Karo Bio’s projects focus on nuclear receptors as target proteins for the development of new pharmaceuticals. It says that it has two in-house projects in clinical development phase, one in preclinical development, and one in early discovery phase. The company also has partnered programs with Merck & Co. in women’s health and multiple scleroris, Alkerm in dyslipidemia, and Zydus Cadila in inflammatory diseases.

    Additionally it has a separate agreement with Pfizer, which began in 2001 with Pfizer’s now wholly owned subsidiary Wyeth. It focuses on the development of new drugs for the treatment of inflammatory diseases with the liver X receptor as a target protein. From September 2009, Wyeth took on full responsibility for R&D.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?